RHHBY Stock Recent News

Roche Holding (RHHBY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Roche is actively working to enhance laboratory testing capacity for mpox worldwide, the Swiss pharmaceutical company said on Tuesday.

Basel, 20 August 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it is supporting the international response to the mpox global health emergency with its diagnostic tests developed for mpox, formerly known as monkeypox. Mpox, a viral disease that can spread easily between people and from infected animals, was declared a Public Health Emergency of International Concern by the World Health Organization (WHO) (14 August 2024).

David Roche, strategist at Quantum Strategy, discusses the yen carry trade and global markets.

David Roche, strategist at Quantum Strategy, discusses the two factors that will cause it.

Veteran investor David Roche expects a bear market in 2025, caused by smaller-than-expected rate cuts, a slowing U.S. economy and an AI bubble. Those factors could cause a bear market of minus 20% in 2025, maybe starting at the end of this year, but the Fed will have room to adjust, he added.

Swiss pharmaceutical company Roche is considering divesting cancer data specialist Flatiron Health, the Financial Times reported on Wednesday, citing people familiar with the matter.

Basel, 30 July 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission (EC) has approved Vabysmo® (faricimab) for the treatment of visual impairment due to macular edema secondary to retinal vein occlusion (RVO, branch RVO or central RVO). RVO is the third indication for Vabysmo in the European Union, in addition to neovascular or ‘wet' age-related macular degeneration (nAMD) and diabetic macular edema (DME).1 Together, the three retinal conditions affect close to 80 million people worldwide and are among the leading causes of vision loss.2-5

Pharmaceutical giant Roche is "fast-tracking" its own weight-loss pills in clinical trials as it looks to compete with Novo Nordisk's Wegovy and Eli Lilly's Zepbound.

Swiss pharmaceutical giant Roche said Monday it is accelerating the development of its Wegovy rival weight loss drugs following promising early stage trial data. The company's two obesity drug candidates are progressing to the next phase of trials and could come to market within the next few years.